Biocon Malaysia Receives EMA Approval for New Drug Product Fill Finish Unit for Insulins

  • Posted by: Biocon Biologics

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Bengaluru, Karnataka, India, July 16, 2026

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.

Supplies to Europe from this line are expected to begin from Q2FY27.

– Company Spokesperson

Author: Biocon Biologics